Early antibody responses associated with survival in COVID19 patients
Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate C...
Gespeichert in:
| Veröffentlicht in: | PLoS pathogens 2021-07, Vol.17 (7), p.e1009766-e1009766 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1009766 |
|---|---|
| container_issue | 7 |
| container_start_page | e1009766 |
| container_title | PLoS pathogens |
| container_volume | 17 |
| creator | Zhou, Zhao-Hua Dharmarajan, Sai Lehtimaki, Mari Kirshner, Susan L Kozlowski, Steven |
| description | Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. |
| doi_str_mv | 10.1371/journal.ppat.1009766 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2561941125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A670983287</galeid><doaj_id>oai_doaj_org_article_a29925e0ff36467098d21d714b14b092</doaj_id><sourcerecordid>A670983287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c638t-8871fa228d016a6c8e56e85731bf1169549b323d25b2fed2abf1f559c07c0fb83</originalsourceid><addsrcrecordid>eNqVkl2L1DAUhoso7rr6DwQL3ujFjDn5anojLOOoA4sLft2GNE1mM3SabtKOzr833aliZW8kgYST57wn7-Fk2XNASyAFvNn5IbSqWXad6peAUFlw_iA7B8bIoiAFffjX_Sx7EuMOIQoE-OPsjFAsEKb0PFuvVWiOuWp7V_n6mAcTO99GE3MVo9dO9abOf7j-Jo9DOLiDanLX5qvr75t3UOaptDNtH59mj6xqonk2nRfZt_frr6uPi6vrD5vV5dVCcyL6hRAFWIWxqBFwxbUwjBvBCgKVBeAlo2VFMKkxq7A1NVYpbBkrNSo0spUgF9mLk27X-CinDkSJGYeSAmCWiM2JqL3ayS64vQpH6ZWTdwEftlKF3unGSIXLEjODrCWc8gKVosZQF0CrtFGJk9bbqdpQ7U2tk9Ogmpno_KV1N3LrD1IQDBShJPBqEgj-djCxl3sXtWka1Ro_jP9mhGFCYHT28h_0fncTtVXJgGutT3X1KCov7xwQLIpELe-h0qrN3mnfGutSfJbwepaQmN787LdqiFFuvnz-D_bTnKUnVgcfYzD2T-8AyXGIf5uU4xDLaYjJLyO04R0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561941125</pqid></control><display><type>article</type><title>Early antibody responses associated with survival in COVID19 patients</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><creator>Zhou, Zhao-Hua ; Dharmarajan, Sai ; Lehtimaki, Mari ; Kirshner, Susan L ; Kozlowski, Steven</creator><creatorcontrib>Zhou, Zhao-Hua ; Dharmarajan, Sai ; Lehtimaki, Mari ; Kirshner, Susan L ; Kozlowski, Steven</creatorcontrib><description>Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data.</description><identifier>ISSN: 1553-7374</identifier><identifier>ISSN: 1553-7366</identifier><identifier>EISSN: 1553-7374</identifier><identifier>DOI: 10.1371/journal.ppat.1009766</identifier><identifier>PMID: 34280244</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Antibodies ; Antigen-antibody reactions ; Antigens ; Biology and Life Sciences ; Care and treatment ; Clinical trials ; Coronaviruses ; COVID-19 ; Disease transmission ; Hospital patients ; Hospitalization ; Immunoassay ; Immunological research ; Medicine and Health Sciences ; Monoclonal antibodies ; Mortality ; Patient outcomes ; Patients ; Prediction models ; Proteins ; Research and Analysis Methods ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Vaccines</subject><ispartof>PLoS pathogens, 2021-07, Vol.17 (7), p.e1009766-e1009766</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c638t-8871fa228d016a6c8e56e85731bf1169549b323d25b2fed2abf1f559c07c0fb83</citedby><cites>FETCH-LOGICAL-c638t-8871fa228d016a6c8e56e85731bf1169549b323d25b2fed2abf1f559c07c0fb83</cites><orcidid>0000-0002-7240-3605 ; 0000-0002-9287-5810 ; 0000-0002-3265-4805 ; 0000-0002-7869-9064</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321400/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321400/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids></links><search><creatorcontrib>Zhou, Zhao-Hua</creatorcontrib><creatorcontrib>Dharmarajan, Sai</creatorcontrib><creatorcontrib>Lehtimaki, Mari</creatorcontrib><creatorcontrib>Kirshner, Susan L</creatorcontrib><creatorcontrib>Kozlowski, Steven</creatorcontrib><title>Early antibody responses associated with survival in COVID19 patients</title><title>PLoS pathogens</title><description>Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data.</description><subject>Antibodies</subject><subject>Antigen-antibody reactions</subject><subject>Antigens</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Disease transmission</subject><subject>Hospital patients</subject><subject>Hospitalization</subject><subject>Immunoassay</subject><subject>Immunological research</subject><subject>Medicine and Health Sciences</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prediction models</subject><subject>Proteins</subject><subject>Research and Analysis Methods</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Vaccines</subject><issn>1553-7374</issn><issn>1553-7366</issn><issn>1553-7374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqVkl2L1DAUhoso7rr6DwQL3ujFjDn5anojLOOoA4sLft2GNE1mM3SabtKOzr833aliZW8kgYST57wn7-Fk2XNASyAFvNn5IbSqWXad6peAUFlw_iA7B8bIoiAFffjX_Sx7EuMOIQoE-OPsjFAsEKb0PFuvVWiOuWp7V_n6mAcTO99GE3MVo9dO9abOf7j-Jo9DOLiDanLX5qvr75t3UOaptDNtH59mj6xqonk2nRfZt_frr6uPi6vrD5vV5dVCcyL6hRAFWIWxqBFwxbUwjBvBCgKVBeAlo2VFMKkxq7A1NVYpbBkrNSo0spUgF9mLk27X-CinDkSJGYeSAmCWiM2JqL3ayS64vQpH6ZWTdwEftlKF3unGSIXLEjODrCWc8gKVosZQF0CrtFGJk9bbqdpQ7U2tk9Ogmpno_KV1N3LrD1IQDBShJPBqEgj-djCxl3sXtWka1Ro_jP9mhGFCYHT28h_0fncTtVXJgGutT3X1KCov7xwQLIpELe-h0qrN3mnfGutSfJbwepaQmN787LdqiFFuvnz-D_bTnKUnVgcfYzD2T-8AyXGIf5uU4xDLaYjJLyO04R0</recordid><startdate>20210719</startdate><enddate>20210719</enddate><creator>Zhou, Zhao-Hua</creator><creator>Dharmarajan, Sai</creator><creator>Lehtimaki, Mari</creator><creator>Kirshner, Susan L</creator><creator>Kozlowski, Steven</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7240-3605</orcidid><orcidid>https://orcid.org/0000-0002-9287-5810</orcidid><orcidid>https://orcid.org/0000-0002-3265-4805</orcidid><orcidid>https://orcid.org/0000-0002-7869-9064</orcidid></search><sort><creationdate>20210719</creationdate><title>Early antibody responses associated with survival in COVID19 patients</title><author>Zhou, Zhao-Hua ; Dharmarajan, Sai ; Lehtimaki, Mari ; Kirshner, Susan L ; Kozlowski, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c638t-8871fa228d016a6c8e56e85731bf1169549b323d25b2fed2abf1f559c07c0fb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antigen-antibody reactions</topic><topic>Antigens</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Disease transmission</topic><topic>Hospital patients</topic><topic>Hospitalization</topic><topic>Immunoassay</topic><topic>Immunological research</topic><topic>Medicine and Health Sciences</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prediction models</topic><topic>Proteins</topic><topic>Research and Analysis Methods</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Zhao-Hua</creatorcontrib><creatorcontrib>Dharmarajan, Sai</creatorcontrib><creatorcontrib>Lehtimaki, Mari</creatorcontrib><creatorcontrib>Kirshner, Susan L</creatorcontrib><creatorcontrib>Kozlowski, Steven</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS pathogens</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Zhao-Hua</au><au>Dharmarajan, Sai</au><au>Lehtimaki, Mari</au><au>Kirshner, Susan L</au><au>Kozlowski, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early antibody responses associated with survival in COVID19 patients</atitle><jtitle>PLoS pathogens</jtitle><date>2021-07-19</date><risdate>2021</risdate><volume>17</volume><issue>7</issue><spage>e1009766</spage><epage>e1009766</epage><pages>e1009766-e1009766</pages><issn>1553-7374</issn><issn>1553-7366</issn><eissn>1553-7374</eissn><abstract>Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>34280244</pmid><doi>10.1371/journal.ppat.1009766</doi><orcidid>https://orcid.org/0000-0002-7240-3605</orcidid><orcidid>https://orcid.org/0000-0002-9287-5810</orcidid><orcidid>https://orcid.org/0000-0002-3265-4805</orcidid><orcidid>https://orcid.org/0000-0002-7869-9064</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1553-7374 |
| ispartof | PLoS pathogens, 2021-07, Vol.17 (7), p.e1009766-e1009766 |
| issn | 1553-7374 1553-7366 1553-7374 |
| language | eng |
| recordid | cdi_plos_journals_2561941125 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Public Library of Science (PLoS) |
| subjects | Antibodies Antigen-antibody reactions Antigens Biology and Life Sciences Care and treatment Clinical trials Coronaviruses COVID-19 Disease transmission Hospital patients Hospitalization Immunoassay Immunological research Medicine and Health Sciences Monoclonal antibodies Mortality Patient outcomes Patients Prediction models Proteins Research and Analysis Methods Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccines |
| title | Early antibody responses associated with survival in COVID19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T00%3A05%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20antibody%20responses%20associated%20with%20survival%20in%20COVID19%20patients&rft.jtitle=PLoS%20pathogens&rft.au=Zhou,%20Zhao-Hua&rft.date=2021-07-19&rft.volume=17&rft.issue=7&rft.spage=e1009766&rft.epage=e1009766&rft.pages=e1009766-e1009766&rft.issn=1553-7374&rft.eissn=1553-7374&rft_id=info:doi/10.1371/journal.ppat.1009766&rft_dat=%3Cgale_plos_%3EA670983287%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2561941125&rft_id=info:pmid/34280244&rft_galeid=A670983287&rft_doaj_id=oai_doaj_org_article_a29925e0ff36467098d21d714b14b092&rfr_iscdi=true |